Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection

Chen, C; Amelia, A; Ashdown, GW; Mueller, I; Coussens, AK; Eriksson, EM

Author(s): Chen, C; Amelia, A; Ashdown, GW; Mueller, I; Coussens, AK; Eriksson, EM;
Details: Publication Year 2021-12-20,Volume 27,Issue #1,Page 160
Journal Title: Molecular Medicine
Abstract: COVID-19 clinical presentation differs considerably between individuals, ranging from asymptomatic, mild/moderate and severe disease which in some cases are fatal or result in long-term effects. Identifying immune mechanisms behind severe disease development informs screening strategies to predict who are at greater risk of developing life-threatening complications. However, to date clear prognostic indicators of individual risk of severe or long COVID remain elusive. Autoantibodies recognize a range of self-antigens and upon antigen recognition and binding, important processes involved in inflammation, pathogen defence and coagulation are modified. Recent studies report a significantly higher prevalence of autoantibodies that target immunomodulatory proteins including cytokines, chemokines, complement components, and cell surface proteins in COVID-19 patients experiencing severe disease compared to those who experience mild or asymptomatic infections. Here we discuss the diverse impacts of autoantibodies on immune processes and associations with severe COVID-19 disease.
Publisher: BMC
Keywords: Animals; Autoantibodies/*immunology/*metabolism; Autoimmunity/physiology; COVID-19/*complications/*immunology/metabolism; Humans; SARS-CoV-2/*immunology/metabolism; *Autoantibodies; *Autoimmunity; *covid-19; *SARS-CoV-2
Research Division(s): Population Health And Immunity; Infectious Diseases And Immune Defence
PubMed ID: 34930107
Publisher's Version: https://doi.org/10.1186/s10020-021-00422-z
Open Access at Publisher's Site: https://doi.org/10.1186/s10020-021-00422-z
Terms of Use/Rights Notice: Refer to copyright notice on published article.
Documents: s10020-021-00422-z.pdf - (3.26MB, application/pdf)

Creation Date: 2022-01-31 05:04:26

Last Modified: 2022-01-31 05:10:32